Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 8 (2011), Issue 1 (January)

1. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study.
   Lancet Oncol, 12(1): 30-7. [Abstract] [Full-text]
2. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets.
   Nat Rev Drug Discov, 10(1): 29-46. [Abstract] [Full-text]
3. Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces.
   J Biol Chem, 286(1): 123-30. [Abstract] [Full-text]
4. Poly(ethylene glycol)-conjugated multi-walled carbon nanotubes as an efficient drug carrier for overcoming multidrug resistance.
   Toxicol Appl Pharmacol, 250(2): 184-93. [Abstract] [Full-text]
5. Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer.
   Cancer Chemother Pharmacol, 67(1): 215-21. [Abstract] [Full-text]
6. Multicentre phase II study of XELOX with bevacizumab in late-stage elderly patients with unresectable advanced/recurrent colorectal cancer: an ASCA study.
   Jpn J Clin Oncol, 41(1): 134-8. [Abstract] [Full-text]
7. A multicenter phase-II study of 5-FU, leucovorin and oxaliplatin (FOLFOX6) in patients with pretreated metastatic colorectal cancer.
   Jpn J Clin Oncol, 41(1): 63-8. [Abstract] [Full-text]
8. A phase II study of cisplatin and irinotecan as induction chemotherapy followed by concomitant thoracic radiotherapy with weekly low-dose irinotecan in unresectable, stage III, non-small cell lung cancer: JCOG 9706.
   Jpn J Clin Oncol, 41(1): 25-31. [Abstract] [Full-text]
9. Proteasome inhibitor bortezomib targeted tumor-endothelial cell interaction in T-cell leukemia/lymphoma.
   Ann Hematol, 90(1): 53-8. [Abstract] [Full-text]
10. Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model.
    Cancer Chemother Pharmacol, 67(1): 193-200. [Abstract] [Full-text]
11. Mitomycin-C- or cisplatin-based chemoradiotherapy for anal canal carcinoma: long-term results.
    Int J Radiat Oncol Biol Phys, 79(2): 490-5. [Abstract] [Full-text]
12. Antegrade subinguinal sclerotization with temporary clamping of the spermatic cord: a new surgical technique for varicocele.
    Urology, 77(1): 223-6. [Abstract] [Full-text]
13. Antitumoral and antimetastatic effects of metronomic chemotherapy with cyclophosphamide combined with celecoxib on murine mammary adenocarcinomas.
    J Cancer Res Clin Oncol, 137(1): 151-63. [Abstract] [Full-text]
14. Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase.
    Cancer Chemother Pharmacol, 67(1): 183-92. [Abstract] [Full-text]
15. Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial.
    Cancer Chemother Pharmacol, 67(1): 153-63. [Abstract] [Full-text]
16. Oral bioavailability of DN101, a concentrated formulation of calcitriol, in tumor-bearing dogs.
    Cancer Chemother Pharmacol, 67(1): 165-71. [Abstract] [Full-text]
17. Phase II study of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin.
    Cancer Chemother Pharmacol, 67(1): 147-52. [Abstract] [Full-text]
18. Circulating levels of angiogenic cytokines in advanced breast cancer patients with system chemotherapy and their potential value in monitoring disease course.
    J Cancer Res Clin Oncol, 137(1): 55-63. [Abstract] [Full-text]
19. Biweekly vinorelbine and gemcitabine as second-line and beyond treatment in ovarian cancer.
    Cancer Chemother Pharmacol, 67(1): 69-73. [Abstract] [Full-text]
20. Extensive dural sinus thrombosis: successful recanalization with thrombolysis and a novel thrombectomy device.
    J Neurosurg, 114(1): 133-5. [Abstract] [Full-text]
21. Mechanical and chemical thrombolysis of cerebral sinus thrombosis: evolution of a technique.
    J Neurosurg, 114(1): 136-9. [Abstract] [Full-text]
22. Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial.
    Cancer Chemother Pharmacol, 67(1): 41-8. [Abstract] [Full-text]
23. Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma.
    Cancer Chemother Pharmacol, 67(1): 75-82. [Abstract] [Full-text]
24. Poly(ethylene glycol)-conjugated multi-walled carbon nanotubes as an efficient drug carrier for overcoming multidrug resistance.
    Toxicol Appl Pharmacol, 250(2): 184-93. [Abstract] [Full-text]
25. Mitomycin-C- or cisplatin-based chemoradiotherapy for anal canal carcinoma: long-term results.
    Int J Radiat Oncol Biol Phys, 79(2): 490-5. [Abstract] [Full-text]
26. Mitomycin-C- or cisplatin-based chemoradiotherapy for anal canal carcinoma: long-term results.
    Int J Radiat Oncol Biol Phys, 79(2): 490-5. [Abstract] [Full-text]
27. Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy.
    Medicine (Baltimore), 90(1): 52-60. [Abstract] [Full-text]
28. Complement factor H and high-temperature requirement A-1 genotypes and treatment response of age-related macular degeneration.
    Ophthalmology, 118(1): 93-100. [Abstract] [Full-text]
29. A tritherapy combination of a fusion protein vaccine with immune-modulating doses of sequential chemotherapies in an optimized regimen completely eradicates large tumors in mice.
    Int J Cancer, 128(5): 1129-38. [Abstract] [Full-text]
30. Targeting IL-13Rα2 in human pancreatic ductal adenocarcinoma with combination therapy of IL-13-PE and gemcitabine.
    Int J Cancer, 128(5): 1221-31. [Abstract] [Full-text]
31. A tritherapy combination of a fusion protein vaccine with immune-modulating doses of sequential chemotherapies in an optimized regimen completely eradicates large tumors in mice.
    Int J Cancer, 128(5): 1129-38. [Abstract] [Full-text]
32. Targeting IL-13Rα2 in human pancreatic ductal adenocarcinoma with combination therapy of IL-13-PE and gemcitabine.
    Int J Cancer, 128(5): 1221-31. [Abstract] [Full-text]
33. A tritherapy combination of a fusion protein vaccine with immune-modulating doses of sequential chemotherapies in an optimized regimen completely eradicates large tumors in mice.
    Int J Cancer, 128(5): 1129-38. [Abstract] [Full-text]
34. Targeting IL-13Rα2 in human pancreatic ductal adenocarcinoma with combination therapy of IL-13-PE and gemcitabine.
    Int J Cancer, 128(5): 1221-31. [Abstract] [Full-text]
35. Active scaffolds for on-demand drug and cell delivery.
    Proc Natl Acad Sci U S A, 108(1): 67-72. [Abstract] [Full-text]
36. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis.
    J Natl Cancer Inst, 103(1): 21-30. [Abstract] [Full-text]
37. Concurrent drug use and the risk of perforated colonic diverticular disease: a population-based case-control study.
    Gut, 60(2): 219-24. [Abstract] [Full-text]
38. Concurrent drug use and the risk of perforated colonic diverticular disease: a population-based case-control study.
    Gut, 60(2): 219-24. [Abstract] [Full-text]
39. Concurrent drug use and the risk of perforated colonic diverticular disease: a population-based case-control study.
    Gut, 60(2): 219-24. [Abstract] [Full-text]
40. Clinical review: Why is androgen replacement in males controversial?
    J Clin Endocrinol Metab, 96(1): 38-52. [Abstract] [Full-text]
41. Effects of photodynamic therapy on rapidly growing nontuberculous mycobacteria keratitis.
    Invest Ophthalmol Vis Sci, 52(1): 223-9. [Abstract] [Full-text]
42. The human glucocorticoid receptor as an RNA-binding protein: global analysis of glucocorticoid receptor-associated transcripts and identification of a target RNA motif.
    J Immunol, 186(2): 1189-98. [Abstract] [Full-text]
43. Mono- and tri-cationic porphyrin-monoclonal antibody conjugates: photodynamic activity and mechanism of action.
    Immunology, 132(2): 256-65. [Abstract] [Full-text]
44. Mono- and tri-cationic porphyrin-monoclonal antibody conjugates: photodynamic activity and mechanism of action.
    Immunology, 132(2): 256-65. [Abstract] [Full-text]
45. Platelet-targeted microbubbles inhibit re-occlusion after thrombolysis with transcutaneous ultrasound and microbubbles.
    Ultrasonics, 51(3): 270-4. [Abstract] [Full-text]
46. Platelet-targeted microbubbles inhibit re-occlusion after thrombolysis with transcutaneous ultrasound and microbubbles.
    Ultrasonics, 51(3): 270-4. [Abstract] [Full-text]
47. Platelet-targeted microbubbles inhibit re-occlusion after thrombolysis with transcutaneous ultrasound and microbubbles.
    Ultrasonics, 51(3): 270-4. [Abstract] [Full-text]
48. Guided interventions in musculoskeletal ultrasound: what's the evidence?
    Clin Radiol, 66(2): 140-52. [Abstract] [Full-text]
49. Dose-dependent toxic effects of high-dose estrogen on renal and cardiac injury in surgically postmenopausal mice.
    Life Sci, 88(3): 178-86. [Abstract] [Full-text]
50. Guided interventions in musculoskeletal ultrasound: what's the evidence?
    Clin Radiol, 66(2): 140-52. [Abstract] [Full-text]
51. Increased antibiotic release from a bone cement containing bacterial cellulose.
    Clin Orthop Relat Res, 469(2): 600-6. [Abstract] [Full-text]
52. Increased antibiotic release from a bone cement containing bacterial cellulose.
    Clin Orthop Relat Res, 469(2): 600-6. [Abstract] [Full-text]
53. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis.
    Ann Hematol, 90(2): 201-6. [Abstract] [Full-text]
54. A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.
    Ann Hematol, 90(2): 193-200. [Abstract] [Full-text]
55. A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy.
    Ann Hematol, 90(2): 185-92. [Abstract] [Full-text]
56. Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia.
    Leukemia, 25(1): 41-7. [Abstract] [Full-text]
57. Convergent assembly and surface modification of multifunctional dendrimers by three consecutive click reactions.
    Chemistry, 17(3): 839-46. [Abstract] [Full-text]
58. Chemoresistant hepatoblastoma in a patient with mosaic trisomy 18 treated with orthotopic liver transplantation.
    Pediatr Blood Cancer, 56(3): 498-500. [Abstract] [Full-text]
59. Bevacizumab and irinotecan in the treatment of children with recurrent/refractory medulloblastoma.
    Pediatr Blood Cancer, 56(3): 491-4. [Abstract] [Full-text]
60. Therapy and outcome of primitive neuroectodermal tumor of the jaw.
    Pediatr Blood Cancer, 56(3): 477-81. [Abstract] [Full-text]
61. High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan.
    Pediatr Blood Cancer, 56(3): 403-8. [Abstract] [Full-text]
62. Chemoresistant hepatoblastoma in a patient with mosaic trisomy 18 treated with orthotopic liver transplantation.
    Pediatr Blood Cancer, 56(3): 498-500. [Abstract] [Full-text]
63. Bevacizumab and irinotecan in the treatment of children with recurrent/refractory medulloblastoma.
    Pediatr Blood Cancer, 56(3): 491-4. [Abstract] [Full-text]
64. Therapy and outcome of primitive neuroectodermal tumor of the jaw.
    Pediatr Blood Cancer, 56(3): 477-81. [Abstract] [Full-text]
65. High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan.
    Pediatr Blood Cancer, 56(3): 403-8. [Abstract] [Full-text]
66. Chemoresistant hepatoblastoma in a patient with mosaic trisomy 18 treated with orthotopic liver transplantation.
    Pediatr Blood Cancer, 56(3): 498-500. [Abstract] [Full-text]
67. Bevacizumab and irinotecan in the treatment of children with recurrent/refractory medulloblastoma.
    Pediatr Blood Cancer, 56(3): 491-4. [Abstract] [Full-text]
68. Therapy and outcome of primitive neuroectodermal tumor of the jaw.
    Pediatr Blood Cancer, 56(3): 477-81. [Abstract] [Full-text]
69. High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan.
    Pediatr Blood Cancer, 56(3): 403-8. [Abstract] [Full-text]
70. Overprescription of postoperative narcotics: a look at postoperative pain medication delivery, consumption and disposal in urological practice.
    J Urol, 185(2): 551-5. [Abstract] [Full-text]
71. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma.
    J Urol, 185(2): 439-44. [Abstract] [Full-text]
72. Recombinant infectious bursal disease virus carrying hepatitis C virus epitopes.
    J Virol, 85(3): 1408-14. [Abstract] [Full-text]
73. Gem-(R)CHOP versus (R)CHOP: a randomized phase II study of gemcitabine combined with (R)CHOP in untreated aggressive non-Hodgkin's lymphoma--EORTC lymphoma group protocol 20021 (EudraCT number 2004-004635-54).
    Eur J Haematol, 86(2): 111-6. [Abstract] [Full-text]
74. Childbearing intentions of HIV-positive women of reproductive age in Soweto, South Africa: the influence of expanding access to HAART in an HIV hyperendemic setting.
    Am J Public Health, 101(2): 350-8. [Abstract] [Full-text]
75. Overprescription of postoperative narcotics: a look at postoperative pain medication delivery, consumption and disposal in urological practice.
    J Urol, 185(2): 551-5. [Abstract] [Full-text]
76. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma.
    J Urol, 185(2): 439-44. [Abstract] [Full-text]
77. Recombinant infectious bursal disease virus carrying hepatitis C virus epitopes.
    J Virol, 85(3): 1408-14. [Abstract] [Full-text]
78. Gem-(R)CHOP versus (R)CHOP: a randomized phase II study of gemcitabine combined with (R)CHOP in untreated aggressive non-Hodgkin's lymphoma--EORTC lymphoma group protocol 20021 (EudraCT number 2004-004635-54).
    Eur J Haematol, 86(2): 111-6. [Abstract] [Full-text]
79. Childbearing intentions of HIV-positive women of reproductive age in Soweto, South Africa: the influence of expanding access to HAART in an HIV hyperendemic setting.
    Am J Public Health, 101(2): 350-8. [Abstract] [Full-text]
80. Targeted iron oxide particles for in vivo magnetic resonance detection of atherosclerotic lesions with antibodies directed to oxidation-specific epitopes.
    J Am Coll Cardiol, 57(3): 337-47. [Abstract] [Full-text]
81. Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells.
    Blood, 117(2): 608-17. [Abstract] [Full-text]
82. Relevance of a prolonged preoperative antibiotic regime in the treatment of bisphosphonate-related osteonecrosis of the jaw.
    J Oral Maxillofac Surg, 69(2): 362-80. [Abstract] [Full-text]
83. Efficacy of a new hypotonic oral rehydration solution containing zinc and prebiotics in the treatment of childhood acute diarrhea: a randomized controlled trial.
    J Pediatr, 158(2): 288-92.e1. [Abstract] [Full-text]
84. Optimal duration of prophylactic antibiotic administration for elective colon cancer surgery: A randomized, clinical trial.
    Surgery, 149(2): 171-8. [Abstract] [Full-text]
85. Gambogic acid enhances proteasome inhibitor-induced anticancer activity.
    Cancer Lett, 301(2): 221-8. [Abstract] [Full-text]
86. Relevance of a prolonged preoperative antibiotic regime in the treatment of bisphosphonate-related osteonecrosis of the jaw.
    J Oral Maxillofac Surg, 69(2): 362-80. [Abstract] [Full-text]
87. Efficacy of a new hypotonic oral rehydration solution containing zinc and prebiotics in the treatment of childhood acute diarrhea: a randomized controlled trial.
    J Pediatr, 158(2): 288-92.e1. [Abstract] [Full-text]
88. Optimal duration of prophylactic antibiotic administration for elective colon cancer surgery: A randomized, clinical trial.
    Surgery, 149(2): 171-8. [Abstract] [Full-text]
89. Gambogic acid enhances proteasome inhibitor-induced anticancer activity.
    Cancer Lett, 301(2): 221-8. [Abstract] [Full-text]
90. Gambogic acid enhances proteasome inhibitor-induced anticancer activity.
    Cancer Lett, 301(2): 221-8. [Abstract] [Full-text]
91. Polymeric nanocapsules ultra stable in complex biological media.
    Colloids Surf B Biointerfaces, 83(2): 376-81. [Abstract] [Full-text]
92. Physicochemical properties of nevirapine-loaded solid lipid nanoparticles and nanostructured lipid carriers.
    Colloids Surf B Biointerfaces, 83(2): 299-306. [Abstract] [Full-text]
93. Characterization of complexes formed by polypropylene imine dendrimers and anti-HIV oligonucleotides.
    Colloids Surf B Biointerfaces, 83(2): 360-6. [Abstract] [Full-text]
94. Self-assembled micelles based on hydrophobically modified quaternized cellulose for drug delivery.
    Colloids Surf B Biointerfaces, 83(2): 313-20. [Abstract] [Full-text]
95. Novel nanogels as drug delivery systems for poorly soluble anticancer drugs.
    Colloids Surf B Biointerfaces, 83(2): 237-44. [Abstract] [Full-text]
96. Carbosilane dendrimers NN8 and NN16 form a stable complex with siGAG1.
    Colloids Surf B Biointerfaces, 83(2): 388-91. [Abstract] [Full-text]
97. Polymeric nanocapsules ultra stable in complex biological media.
    Colloids Surf B Biointerfaces, 83(2): 376-81. [Abstract] [Full-text]
98. Physicochemical properties of nevirapine-loaded solid lipid nanoparticles and nanostructured lipid carriers.
    Colloids Surf B Biointerfaces, 83(2): 299-306. [Abstract] [Full-text]
99. Characterization of complexes formed by polypropylene imine dendrimers and anti-HIV oligonucleotides.
    Colloids Surf B Biointerfaces, 83(2): 360-6. [Abstract] [Full-text]
100. Self-assembled micelles based on hydrophobically modified quaternized cellulose for drug delivery.
     Colloids Surf B Biointerfaces, 83(2): 313-20. [Abstract] [Full-text]
101. Novel nanogels as drug delivery systems for poorly soluble anticancer drugs.
     Colloids Surf B Biointerfaces, 83(2): 237-44. [Abstract] [Full-text]
102. Carbosilane dendrimers NN8 and NN16 form a stable complex with siGAG1.
     Colloids Surf B Biointerfaces, 83(2): 388-91. [Abstract] [Full-text]
103. Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed uninfected infants in Botswana.
     J Acquir Immune Defic Syndr, 56(2): 131-8. [Abstract] [Full-text]
104. Antiretroviral drugs in the cupboard are not enough: the impact of health systems' performance on mother-to-child transmission of HIV.
     J Acquir Immune Defic Syndr, 56(2): e45-8. [Abstract] [Full-text]
105. Written action plan in pediatric emergency room improves asthma prescribing, adherence, and control.
     Am J Respir Crit Care Med, 183(2): 195-203. [Abstract] [Full-text]
106. Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed uninfected infants in Botswana.
     J Acquir Immune Defic Syndr, 56(2): 131-8. [Abstract] [Full-text]
107. Antiretroviral drugs in the cupboard are not enough: the impact of health systems' performance on mother-to-child transmission of HIV.
     J Acquir Immune Defic Syndr, 56(2): e45-8. [Abstract] [Full-text]
108. Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer.
     Br J Cancer, 104(2): 265-71. [Abstract] [Full-text]
109. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate.
     J Clin Oncol, 29(3): 310-5. [Abstract] [Full-text]
110. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study.
     J Clin Oncol, 29(3): 264-71. [Abstract] [Full-text]
111. Localization of the motor endplate zone in human skeletal muscles of the lower limb: anatomical guidelines for injection with botulinum toxin.
     Dev Med Child Neurol, 53(2): 108-19. [Abstract] [Full-text]
112. Localization of the motor endplate zone in human skeletal muscles of the lower limb: anatomical guidelines for injection with botulinum toxin.
     Dev Med Child Neurol, 53(2): 108-19. [Abstract] [Full-text]
113. Iniparib plus chemotherapy in metastatic triple-negative breast cancer.
     N Engl J Med, 364(3): 205-14. [Abstract] [Full-text]
114. Follow-up survey of children who received sulfadoxine-pyrimethamine for intermittent preventive antimalarial treatment in infants.
     J Infect Dis, 203(4): 556-60. [Abstract] [Full-text]
115. Iniparib plus chemotherapy in metastatic triple-negative breast cancer.
     N Engl J Med, 364(3): 205-14. [Abstract] [Full-text]
116. Normalization of FoxP3(+) regulatory T cells in response to effective antiretroviral therapy.
     J Infect Dis, 203(4): 496-9. [Abstract] [Full-text]
117. Follow-up survey of children who received sulfadoxine-pyrimethamine for intermittent preventive antimalarial treatment in infants.
     J Infect Dis, 203(4): 556-60. [Abstract] [Full-text]
118. Normalization of FoxP3(+) regulatory T cells in response to effective antiretroviral therapy.
     J Infect Dis, 203(4): 496-9. [Abstract] [Full-text]
119. Estrogen receptor polymorphisms and the vascular effects of hormone therapy.
     Arterioscler Thromb Vasc Biol, 31(2): 464-9. [Abstract] [Full-text]
120. Pleth variability index predicts fluid responsiveness in critically ill patients.
     Crit Care Med, 39(2): 294-9. [Abstract] [Full-text]
121. Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality.
     Crit Care Med, 39(2): 259-65. [Abstract] [Full-text]
122. Follow-up survey of children who received sulfadoxine-pyrimethamine for intermittent preventive antimalarial treatment in infants.
     J Infect Dis, 203(4): 556-60. [Abstract] [Full-text]
123. Normalization of FoxP3(+) regulatory T cells in response to effective antiretroviral therapy.
     J Infect Dis, 203(4): 496-9. [Abstract] [Full-text]
124. Microperimetric changes after photodynamic therapy for central serous chorioretinopathy.
     Am J Ophthalmol, 151(2): 303-9.e1. [Abstract] [Full-text]
125. Survey of intravitreal injection techniques among retinal specialists in the United States.
     Am J Ophthalmol, 151(2): 329-32. [Abstract] [Full-text]
126. Experimental study of radioimmunotherapy versus chemotherapy for colorectal cancer.
     Br J Surg, 98(3): 436-41. [Abstract] [Full-text]
127. Refining the benefit-risk framework for the assessment of medicines: valuing and weighting benefit and risk parameters.
     Clin Pharmacol Ther, 89(2): 179-82. [Abstract] [Full-text]
128. Microperimetric changes after photodynamic therapy for central serous chorioretinopathy.
     Am J Ophthalmol, 151(2): 303-9.e1. [Abstract] [Full-text]
129. Survey of intravitreal injection techniques among retinal specialists in the United States.
     Am J Ophthalmol, 151(2): 329-32. [Abstract] [Full-text]
130. Experimental study of radioimmunotherapy versus chemotherapy for colorectal cancer.
     Br J Surg, 98(3): 436-41. [Abstract] [Full-text]
131. Experimental study of radioimmunotherapy versus chemotherapy for colorectal cancer.
     Br J Surg, 98(3): 436-41. [Abstract] [Full-text]
132. In vivo toxicity and immunogenicity of wheat germ agglutinin conjugated poly(ethylene glycol)-poly(lactic acid) nanoparticles for intranasal delivery to the brain.
     Toxicol Appl Pharmacol, 251(1): 79-84. [Abstract] [Full-text]
133. FOXO3a reactivation mediates the synergistic cytotoxic effects of rapamycin and cisplatin in oral squamous cell carcinoma cells.
     Toxicol Appl Pharmacol, 251(1): 8-15. [Abstract] [Full-text]
134. Mechanisms of epileptogenesis and potential treatment targets.
     Lancet Neurol, 10(2): 173-86. [Abstract] [Full-text]
135. In vivo toxicity and immunogenicity of wheat germ agglutinin conjugated poly(ethylene glycol)-poly(lactic acid) nanoparticles for intranasal delivery to the brain.
     Toxicol Appl Pharmacol, 251(1): 79-84. [Abstract] [Full-text]
136. The successful use of low-dose recombinant tissue plasminogen activator for treatment of intracardiac/pulmonary thrombosis during liver transplantation.
     Anesth Analg, 112(2): 319-21. [Abstract] [Full-text]
137. Prostaglandin E receptors as inflammatory therapeutic targets for atherosclerosis.
     Life Sci, 88(5): 201-5. [Abstract] [Full-text]
138. A lysine-free mutant of epidermal growth factor as targeting moiety of a targeted toxin.
     Life Sci, 88(5): 226-32. [Abstract] [Full-text]
139. FOXO3a reactivation mediates the synergistic cytotoxic effects of rapamycin and cisplatin in oral squamous cell carcinoma cells.
     Toxicol Appl Pharmacol, 251(1): 8-15. [Abstract] [Full-text]
140. Injectability of silicone oil-based tamponade agents.
     Br J Ophthalmol, 95(2): 273-6. [Abstract] [Full-text]
141. Efficacy of hormone therapy for osteoporosis in adolescent girls after hematopoietic stem cell transplantation: a longitudinal study.
     Fertil Steril, 95(2): 731-5. [Abstract] [Full-text]
142. Non-laxative CT colonography with barium-based faecal tagging: is additional phosphate enema beneficial and well tolerated?
     Br J Radiol, 84(998): 120-5. [Abstract] [Full-text]
143. Thalidomide treatment attenuates chemotherapy-induced gonadal toxicity.
     Fertil Steril, 95(2): 819-22. [Abstract] [Full-text]
144. Antibiotic prophylaxis for hysteroscopy evaluation of the uterine cavity.
     Fertil Steril, 95(2): 792-4. [Abstract] [Full-text]
145. Embryo yield after in vitro fertilization in women undergoing embryo banking for fertility preservation before chemotherapy.
     Fertil Steril, 95(2): 588-91. [Abstract] [Full-text]
146. In vivo toxicity and immunogenicity of wheat germ agglutinin conjugated poly(ethylene glycol)-poly(lactic acid) nanoparticles for intranasal delivery to the brain.
     Toxicol Appl Pharmacol, 251(1): 79-84. [Abstract] [Full-text]
147. FOXO3a reactivation mediates the synergistic cytotoxic effects of rapamycin and cisplatin in oral squamous cell carcinoma cells.
     Toxicol Appl Pharmacol, 251(1): 8-15. [Abstract] [Full-text]
148. Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma.
     Leuk Res, 35(2): 147-51. [Abstract] [Full-text]
149. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity.
     Leuk Res, 35(2): 183-7. [Abstract] [Full-text]
150. Analysis of triclosan inclusion complexes with β-cyclodextrin and its water-soluble polymeric derivative.
     J Pharm Biomed Anal, 54(5): 1030-9. [Abstract] [Full-text]
151. Association between stroke center hospitalization for acute ischemic stroke and mortality.
     JAMA, 305(4): 373-80. [Abstract] [Full-text]
152. Association between stroke center hospitalization for acute ischemic stroke and mortality.
     JAMA, 305(4): 373-80. [Abstract] [Full-text]
153. The association of shift-level nurse staffing with adverse patient events.
     J Nurs Adm, 41(2): 64-70. [Abstract] [Full-text]
154. New cancer treatment strategy using combination of green tea catechins and anticancer drugs.
     Cancer Sci, 102(2): 317-23. [Abstract] [Full-text]
155. Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer.
     Cancer Sci, 102(2): 425-31. [Abstract] [Full-text]
156. Phase I trial of chemoradiotherapy with the combination of S-1 plus cisplatin for patients with unresectable locally advanced squamous cell carcinoma of the head and neck.
     Cancer Sci, 102(2): 419-24. [Abstract] [Full-text]
157. Evolution of locoregional treatment for peritoneal carcinomatosis: single-center experience of 308 procedures of cytoreductive surgery and perioperative intraperitoneal chemotherapy.
     Am J Surg, 201(2): 149-56. [Abstract] [Full-text]
158. Principles of inner ear sustained release following intratympanic administration.
     Laryngoscope, 121(2): 385-91. [Abstract] [Full-text]
159. Local anesthesia before IV catheterization.
     Am J Nurs, 111(2): 40-5; quiz 46-7. [Abstract] [Full-text]
160. Efficacy of the Boar-Operated-System to deliver baits to feral swine.
     Prev Vet Med, 98(4): 243-9. [Abstract] [Full-text]
161. Randomized study of surgical prophylaxis in immunocompromised hosts.
     J Dent Res, 90(2): 225-9. [Abstract] [Full-text]
162. Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma.
     Am J Clin Oncol, 34(1): 70-5. [Abstract] [Full-text]
163. A pilot study of bevacizumab and interferon-α2b in ocular melanoma.
     Am J Clin Oncol, 34(1): 87-91. [Abstract] [Full-text]
164. Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors.
     Am J Clin Oncol, 34(1): 27-31. [Abstract] [Full-text]
165. Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma: a single institution study.
     Am J Clin Oncol, 34(1): 38-42. [Abstract] [Full-text]
166. The role of chemo-radiotherapy in the management of locally advanced carcinoma of the vulva: single institutional experience and review of literature.
     Am J Clin Oncol, 34(1): 22-6. [Abstract] [Full-text]
167. Age has no significant impact on overall survival and on treatment tolerability in relapsed stage IV cutaneous malignant melanoma patients receiving Cisplatin, Gemcitabine, and Treosulfan.
     Am J Clin Oncol, 34(1): 2-5. [Abstract] [Full-text]
168. Efficacy of the Boar-Operated-System to deliver baits to feral swine.
     Prev Vet Med, 98(4): 243-9. [Abstract] [Full-text]
169. Efficacy of the Boar-Operated-System to deliver baits to feral swine.
     Prev Vet Med, 98(4): 243-9. [Abstract] [Full-text]
170. Topical delivery and photodynamic evaluation of a multivesicular liposomal Rose Bengal.
     Lasers Med Sci, 26(2): 267-75. [Abstract] [Full-text]
171. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
     Lancet Oncol, 12(2): 144-52. [Abstract] [Full-text]
172. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
     Lancet Oncol, 12(2): 153-9. [Abstract] [Full-text]
173. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.
     J Clin Oncol, 29(4): 369-77. [Abstract] [Full-text]
174. Improved prognosis for older adolescents with acute lymphoblastic leukemia.
     J Clin Oncol, 29(4): 386-91. [Abstract] [Full-text]
175. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1.
     J Clin Oncol, 29(4): 449-55. [Abstract] [Full-text]
176. Endovascular therapy for acute limb ischemia.
     J Vasc Surg, 53(2): 340-6. [Abstract] [Full-text]
177. The antimalarial agent artesunate possesses anticancer properties that can be enhanced by combination strategies.
     Int J Cancer, 128(6): 1471-80. [Abstract] [Full-text]
178. Reproductive and hormonal factors and the risk of nonsmall cell lung cancer.
     Int J Cancer, 128(6): 1404-13. [Abstract] [Full-text]
179. The antimalarial agent artesunate possesses anticancer properties that can be enhanced by combination strategies.
     Int J Cancer, 128(6): 1471-80. [Abstract] [Full-text]
180. Reproductive and hormonal factors and the risk of nonsmall cell lung cancer.
     Int J Cancer, 128(6): 1404-13. [Abstract] [Full-text]
181. The antimalarial agent artesunate possesses anticancer properties that can be enhanced by combination strategies.
     Int J Cancer, 128(6): 1471-80. [Abstract] [Full-text]
182. Reproductive and hormonal factors and the risk of nonsmall cell lung cancer.
     Int J Cancer, 128(6): 1404-13. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.